A Bayesian Case Study in Oncology Phase I Combination Dose-Finding Using Logistic Regression with Covariates

A Bayesian approach to finding the maximum tolerated dose (MTD) is presented. The approach is flexible, allowing inclusion of covariates, and enables transparent dose recommendations based on comprehensive inferential summaries on the probability of dose-limiting toxicities (DLT). A case study is presented for a Phase I combination of two oncology drugs, nilotinib and imatinib. Data obtained and decisions made during the study are described. Final determination of the MTD pair is outlined, along with discussion regarding the use and interpretability of within- and end-of-study data.

[1]  Peter F Thall,et al.  Dose‐Finding with Two Agents in Phase I Oncology Trials , 2003, Biometrics.

[2]  Petra Matt,et al.  The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP). , 2011, The oncologist.

[3]  S Zacks,et al.  Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[4]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.

[5]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[6]  M. A. Best.  Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .

[7]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.

[8]  Michael Branson,et al.  Critical aspects of the Bayesian approach to phase I cancer trials , 2008, Statistics in medicine.

[9]  J. Ledermann.  Phase I Cancer Clinical Trials , 2007, British Journal of Cancer.

[10]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON CLINICAL TRIALS IN SMALL POPULATIONS , 2005 .

[11]  Steven Joffe,et al.  Rethinking risk-benefit assessment for phase I cancer trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.